Once- or twice-daily non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation: A meta-analysis of randomized controlled trials
作者: Kang-Ling WangChun-Chih ChiuDoreen Su-Yin TanChun-Yi LinEn-Yu LaiShinya GotoRobert P. GiuglianoChern-En Chiang
作者单位: 1General Clinical Research Center, Taipei Veterans General Hospital, Taipei, Taiwan
2School of Medicine, National Yang-Ming University, Taipei, Taiwan
3Department of Pharmacy, Khoo Teck Puat Hospital, Singapore, Singapore
4Institute of Information Science, Academia Sinica, Taipei, Taiwan
5Department of Medicine, Tokai University School of Medicine, Kanagawa, Japan
6Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, USA
刊名: Journal of the Formosan Medical Association, 2017, Vol.116 (8), pp.591-598
来源数据库: Elsevier Journal
DOI: 10.1016/j.jfma.2017.05.015
关键词: Asian patientsAtrial fibrillationNon-vitamin K antagonist oral anticoagulants
英文摘要: Background/Purpose(#br)Non-vitamin K antagonist oral anticoagulants (NOACs) have a half-life of around 12 h. We aimed to clarify if there was any effect modification by dosing (once- or twice-daily) regimens in Asian patients.(#br)Methods(#br)Phase III randomized controlled trials of NOACs compared with warfarin in Asian patients with atrial fibrillation (AF) were identified and extracted from PubMed, CENTRAL, and CINAHL databases through November 2016. Outcomes were pooled by dosing regimens with the Mantel-Haenszel fixed-effects model. The risk ratio (RR) and 95% confidence interval (CI) were calculated. Effect differences between once- and twice-daily NOACs were assessed with Bucher indirect comparisons using common estimates, once heterogeneity was low, and with the Bayesian...
全文获取路径: Elsevier  (合作)

  • fibrillation 原纤维化
  • atrial 围鳃的
  • controlled 受控
  • vitamin 维生素
  • twice 再次
  • antagonist 对抗剂
  • analysis 分析
  • daily 每天的